跳至主要内容
临床试验/NCT02759341
NCT02759341已完成不适用

Tako-Tsubo Cardiomyopathy and Cardiac Syndrome X: a Study on the Brain-heart Interactions in Two Orphan Cardiac Diseases.

Ospedale San Giovanni Bellinzona2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2016年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
50
试验地点
2
主要终点
Difference in BOLD-fMRI intensity signal in CSX and TTC as compared to AMI patients

研究概览

简要总结

The Tako-Tsubo Cardiomyopathy (TTC) and the Cardiac Syndrome X (CSX) are respectively acute and chronic heart diseases, which mimic myocardial infarction and stable angina pectoris without alterations of large coronary vessels. The causes and the most appropriate and best treatment for these diseases have not been yet clarified, but there are indications, that mental and psychosocial aspects may also contribute to these two diseases. So far, there is no study, which has comprehensively evaluated the interactions between mind and heart in these two conditions.

The purpose of this study is to search for possible differences in mental activity, response to stressful events and function of specific areas of the brain deeply involved in relation between mind and heart.

45 subjects will be recruited and divided equally into: patients with CSX, patients with TTC (at least 6 months ago) and patients with previous acute myocardial infarction (at least 6 months ago). All participants will undergo a clinical interview and several questionnaires that assess various mental functions, the stress response and the quality of life. In addition, in a separate visit the participants will undergo a Magnetic Resonance Imaging without contrast medium that helps to assess function of specific areas of the brain.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Group A. 15 patients with Cardiac X Syndrome (CSX), according to the diagnostic criteria previously proposed by Lanza et al.
  • Group B. 15 patients with Tako-Tsubo Cardiomyopathy (TTC), according to Mayo diagnostic criteria at least 6 months after being hospitalized or diagnosed with TTC.
  • Group C (control group). 15 prospectively enrolled patients with previous Type 1, 4a, 4b myocardial infarction (ST-segment elevation acute myocardial infarction [STEMI] and Non ST-segment elevation acute myocardial infarction [NSTEMI] acute coronary syndrome [ACS] with significant ≥70% coronary stenosis) at least six months after the event.
  • Acute myocardial infarction will be defined according to the third universal definition of myocardial infarction.

排除标准

  • Refused consent
  • Unable to participate or provide written informed consent
  • Short-term survival (<1 year)
  • Acute or decompensated medical conditions
  • Acute neurological or psychiatric diseases
  • Absence of sinus rhythm or frequent ectopic beats
  • History of severe lung, liver, kidney or autoimmune diseases
  • Any contraindication to MRI

研究组 & 干预措施

Takotsubo Cardiomyopathy (TTC)

Other

Tako-Tsubo Cardiomyopathy (TTC), according to Mayo diagnostic criteria at least six months after the event. (Prasad A, et al. Am Heart J. 2008)

干预措施: State-Trait Anxiety Inventory form Y (STAI-Y) (Other)

Cardiac X Syndrome (CSX)

Other

patients with Cardiac X Syndrome (CSX), according to the diagnostic criteria previously proposed by Lanza (Lanza, Heart. 2007)

干预措施: Manual for the Assessment and Documentation of Psychopathology (AMDP 8) (Other)

Cardiac X Syndrome (CSX)

Other

patients with Cardiac X Syndrome (CSX), according to the diagnostic criteria previously proposed by Lanza (Lanza, Heart. 2007)

干预措施: Million Clinical Multiaxial Inventory 3 (MCMI-III) (Other)

Cardiac X Syndrome (CSX)

Other

patients with Cardiac X Syndrome (CSX), according to the diagnostic criteria previously proposed by Lanza (Lanza, Heart. 2007)

干预措施: State-Trait Anxiety Inventory form Y (STAI-Y) (Other)

Cardiac X Syndrome (CSX)

Other

patients with Cardiac X Syndrome (CSX), according to the diagnostic criteria previously proposed by Lanza (Lanza, Heart. 2007)

干预措施: SF-36 Health-Related Quality of Life (Other)

Cardiac X Syndrome (CSX)

Other

patients with Cardiac X Syndrome (CSX), according to the diagnostic criteria previously proposed by Lanza (Lanza, Heart. 2007)

干预措施: Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI) (Other)

Takotsubo Cardiomyopathy (TTC)

Other

Tako-Tsubo Cardiomyopathy (TTC), according to Mayo diagnostic criteria at least six months after the event. (Prasad A, et al. Am Heart J. 2008)

干预措施: SF-36 Health-Related Quality of Life (Other)

Takotsubo Cardiomyopathy (TTC)

Other

Tako-Tsubo Cardiomyopathy (TTC), according to Mayo diagnostic criteria at least six months after the event. (Prasad A, et al. Am Heart J. 2008)

干预措施: Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI) (Other)

Takotsubo Cardiomyopathy (TTC)

Other

Tako-Tsubo Cardiomyopathy (TTC), according to Mayo diagnostic criteria at least six months after the event. (Prasad A, et al. Am Heart J. 2008)

干预措施: Manual for the Assessment and Documentation of Psychopathology (AMDP 8) (Other)

Takotsubo Cardiomyopathy (TTC)

Other

Tako-Tsubo Cardiomyopathy (TTC), according to Mayo diagnostic criteria at least six months after the event. (Prasad A, et al. Am Heart J. 2008)

干预措施: Million Clinical Multiaxial Inventory 3 (MCMI-III) (Other)

Acute myocardial infarction (AMI)

Other

Type 1, 4a, 4b myocardial infarction (ST-segment elevation acute myocardial infarction [STEMI] and Non ST-segment elevation acute myocardial infarction [NSTEMI] acute coronary syndrome [ACS] with significant ≥70% coronary stenosis) at least six months after the event. (Thygesen K, et al. Eur Heart J. 2012)

干预措施: Manual for the Assessment and Documentation of Psychopathology (AMDP 8) (Other)

Acute myocardial infarction (AMI)

Other

Type 1, 4a, 4b myocardial infarction (ST-segment elevation acute myocardial infarction [STEMI] and Non ST-segment elevation acute myocardial infarction [NSTEMI] acute coronary syndrome [ACS] with significant ≥70% coronary stenosis) at least six months after the event. (Thygesen K, et al. Eur Heart J. 2012)

干预措施: Million Clinical Multiaxial Inventory 3 (MCMI-III) (Other)

Acute myocardial infarction (AMI)

Other

Type 1, 4a, 4b myocardial infarction (ST-segment elevation acute myocardial infarction [STEMI] and Non ST-segment elevation acute myocardial infarction [NSTEMI] acute coronary syndrome [ACS] with significant ≥70% coronary stenosis) at least six months after the event. (Thygesen K, et al. Eur Heart J. 2012)

干预措施: State-Trait Anxiety Inventory form Y (STAI-Y) (Other)

Acute myocardial infarction (AMI)

Other

Type 1, 4a, 4b myocardial infarction (ST-segment elevation acute myocardial infarction [STEMI] and Non ST-segment elevation acute myocardial infarction [NSTEMI] acute coronary syndrome [ACS] with significant ≥70% coronary stenosis) at least six months after the event. (Thygesen K, et al. Eur Heart J. 2012)

干预措施: SF-36 Health-Related Quality of Life (Other)

Acute myocardial infarction (AMI)

Other

Type 1, 4a, 4b myocardial infarction (ST-segment elevation acute myocardial infarction [STEMI] and Non ST-segment elevation acute myocardial infarction [NSTEMI] acute coronary syndrome [ACS] with significant ≥70% coronary stenosis) at least six months after the event. (Thygesen K, et al. Eur Heart J. 2012)

干预措施: Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI) (Other)

结局指标

主要结局

Difference in BOLD-fMRI intensity signal in CSX and TTC as compared to AMI patients

时间窗: Baseline

Difference in BOLD-fMRI distribution signal in CSX and TTC as compared to AMI patients

时间窗: Baseline

次要结局

  • Difference in CSX and TTC AMDP 8 results as compared to AMI patients(Baseline)
  • Difference in CSX and TTC MCMI-III results as compared to AMI patients(Baseline)
  • Difference in CSX and TTC STAI-Y results as compared to AMI patients(Baseline)
  • Difference in CSX and TTC SF-36 HRQOL results as compared to AMI patients(Baseline)

研究者

发起方
Ospedale San Giovanni Bellinzona
申办方类型
Other
责任方
Principal Investigator
主要研究者

Mattia Cattaneo

M.D.

Ospedale San Giovanni Bellinzona

研究点 (2)

Loading locations...

相似试验